METTL3 and posterior cortical atrophy: These findings are consistent with an oncogenic function of METTL3, with higher expression associated with PCa, a more advanced disease stage and poorer prognosis (Cai et al., 2019; Ji et al., 2020; Ma Z. et al., 2020; Yuan et al., 2020; Haigh et al., 2022).